Dossier assessment

Pitolisant (sleep apnoea) - Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A21-140
Last updated

Report documents

  1. Extract of dossier assessment

    Pitolisant (sleep apnoea) - Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 386 kB, EN, not accessible
  2. Dossier assessment

    Pitolisant (sleep apnoea) - Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 554 kB, DE, not accessible

Dossier assessment

Indication:

Improvement of wakefulness and reduction of excessive daytime sleepiness in adult patients with obstructive sleep apnoea (OSA) whose excessive daytime sleepiness has not been satisfactorily treated by, or who have not tolerated, primary OSA therapy, such as continuous positive airway pressure (CPAP)

Result of dossier assessment:

Added benefit not proven

Project details

Project no.
A21-140
Commission
Commission awarded on 01.11.2021 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Head and nerves
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

The current version 1.1 of the dossier assessment replaces version 1.0 published on 2022-02-01.

Connected Projects

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form